21 March 2011 in EP Europace
Left ventricular (LV) lead placement to the most delayed segment offers the greatest potential benefit to cardiac resynchronization therapy (CRT). We assessed the impact of interventricular (VV) optimization on acute changes in cardiac output (CO) in patients with and without LV pacing of the most delayed segment. In 124 patients, the most delayed segment was defined by speckle tracking radial strain and the LV lead position by biplane fluoroscopy. Patients were classified as either a concordant (LV lead at latest site), adjacent (within one segment), or remote (two or more segments away) LV lead. Atrioventricular (AV) and VV delays were optimized by echocardiography. Cardiac output was measured non-invasively and a >20% increase in CO from baseline (intrinsic) defined acute response. Changes in CO in patients with concordant, adjacent, or remote LV leads were recorded following atrioventricular optimization alone (AV OPT) and after combined AV and VV optimization (AV/VV OPT). Compared with AV OPT pacing, AV/VV OPT produced a greater rise in CO (5.45 ± 1.1 vs. 5.76 ± 1.2 L/min, P< 0.001) and higher acute response rates (48.4 vs. 61.3%, P= 0.041). In adjacent patients, compared with AV OPT pacing, AV/VV OPT settings increased the response rate from 36.4 to 63.6% (P= 0.037). VV optimization had no effect on acute response rates in patients with remote (26.7 vs. 33.3%, P = 0.581) or concordant LV leads (65.6 vs. 72.1%, P = 0.438). VV optimization overcomes some but not all of the deleterious effects of a suboptimal LV lead position.
1 February 2010 in Expert Review of Cardiovascular Therapy
Heart failure is posing an increasing burden on healthcare systems around the world, a consequence of increased survival from acute coronary syndromes and life-prolonging medications. Cardiac resynchronization therapy has become a ratified and established therapy for heart failure to reduce both the morbidity and mortality of the condition. Its prophylactic role in patients who have minimal symptoms to delay future deterioration is a novel development. The indications for this therapy continue to evolve, mainly as a result of company-sponsored multicenter trial data aimed at broadening its usage. Uncertainty remains on how to accurately identify individuals who will respond to resynchronization therapy and how best to manage patients following device implant.
21 May 2010 in European Heart Journal
A 59-year-old Afro-Caribbean woman with a history of tuberculosis, hepatitis C, and excessive alcohol consumption presented to our institution for investigation of her breathlessness, worsening peripheral oedema, acute renal failure, and deranged liver function tests. She had elevated jugular venous pressure, hepatomegaly, gross peripheral oedema, ascites, and signs of chronic liver disease. Despite diuretic therapy and oral fluid restriction, her oedema persisted. Echocardiography demonstrated normal biventricular size and function with no valve pathology. In addition, a large homogeneous mass was seen in the right atrium (Panel A), with finger-like projections extending into the right ventricle during atrial systole and caudal extension into the inferior vena cava (Panel B). She had neither a central venous catheter nor other obvious prothrombotic cause for atrial thrombus formation. It was initially proposed that the mass was most likely atrial myxoma in an unusual position. Ultrasound of the liver, however, demonstrated several nodules consistent with malignancy (Panel C). Computed tomography demonstrated the typical appearance of hepatocellular carcinoma, with associated thrombus, extending from the right lobe of the liver into the hepatic vein and inferior vena cava and into the right atrium (Panel D). Multiple pulmonary nodules, in keeping with pulmonary metastases, and bilateral pulmonary emboli were also seen. She remained unresponsive to diuretic therapy and was discharged home for palliative care.
1 March 2018 in Future Cardiology
A substantial proportion of patients who undergo cardiac device implantation receive oral anticoagulation to prevent thromboembolism or antiplatelets to prevent thrombotic events. Anticoagulation and antiplatelets increase the risk of hemorrhagic complications, while discontinuation may increase thromboembolic risk and thrombotic events. With the introduction of non-vitamin K antagonist oral anticoagulant agents and the newer antiplatelet agents such as prasugrel or ticagrelor, the perioperative management of patients has become more challenging. In this article, we review the recent trials and meta-analysis and describe the available evidence, as well as the current recommendations in order to inform best practice. We also reinforce the importance of further trials in this complex and rapidly evolving area.
18 September 2024 in JACC: Cardiovascular Interventions